{"nctId":"NCT00492063","briefTitle":"Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly","startDateStruct":{"date":"2004-09"},"conditions":["Influenza"],"count":2654,"armGroups":[{"label":"Cell culture-derived influenza vaccine (cTIV)","type":"EXPERIMENTAL","interventionNames":["Biological: Cell culture-derived trivalent subunit influenza vaccine (cTIV)"]},{"label":"Egg-derived influenza virus vaccine (TIV)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Egg-derived trivalent subunit influenza vaccine (TIV)"]}],"interventions":[{"name":"Cell culture-derived trivalent subunit influenza vaccine (cTIV)","otherNames":[]},{"name":"Egg-derived trivalent subunit influenza vaccine (TIV)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 to 60 years of age (first age group) OR over 60 years of age (second age group)\n2. mentally competent to understand the nature, the scope and the consequences of the study\n3. able and willing to give written informed consent prior to study entry\n4. available for all the visits scheduled in the study\n5. residence in the study area\n6. in good health as determined by:\n\n   1. medical history,\n   2. physical examination,\n   3. clinical judgment of the investigator.\n\nExclusion Criteria:\n\n1. unable or unwilling to give written informed consent to participate in the study\n2. suffering from an acute infectious disease\n3. any serious disease such as:\n\n   1. cancer (except for benign or localized skin cancer and non metastatic prostate cancer not currently treated with chemotherapy),\\_\n   2. autoimmune disease (including rheumatoid arthritis),\n   3. advanced arteriosclerotic disease or complicated diabetes mellitus,\n   4. chronic obstructive pulmonary disease (COPD) requiring oxygen therapy,\n   5. acute or progressive hepatic disease,\n   6. acute or progressive renal disease,\n   7. congestive heart failure\n4. surgery planned during the study period\n5. bleeding diathesis\n6. history of hypersensitivity to any component of the study medication or chemically related substances, such as allergy to eggs or egg products\n7. known or suspected impairment/alteration of immune function resulting from:\n\n   1. receipt of immunosuppressive therapy (any cortical steroid or cancer chemotherapy),\n   2. receipt of immunostimulants,\n   3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study,\n   4. high risk for developing an immunocompromising disease within the past 6 months\n8. history of drug or alcohol abuse\n9. laboratory confirmed influenza disease in the past 6 months\n10. received influenza vaccine within the past 6 months\n11. received another vaccine or any investigational agent within the past 60 days, or planned vaccination within 3 weeks following the study vaccination\n12. any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or experienced fever ≥ 38°C within the past 3 days\n13. pregnant women or women who refused to use a reliable contraceptive method throughout the study (180 days)\n14. any condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentages Of Subjects Who Achieved HI Titer ≥40 After One Vaccination of Cell Culture-derived (cTIV) or Egg-derived (TIV) Influenza Subunit Vaccines","description":"Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (day 1) and three weeks (day 22) after one vaccination of cTIV or TIV vaccine for each of three vaccine strains, evaluated using the hemagglutination inhibition (HI) egg-derived antigen assay.\n\nIn compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the percentage of subjects achieving HI titers ≥40 is \\>70% in the ≥18 to ≤60 years of age group or \\>60% in the ≥61 years of age group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"90","spread":null},{"groupId":"OG003","value":"89","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titer After One Vaccination of cTIV or TIV","description":"Seroconversion or significant in HI titer is defined as the percentage of subjects with a prevaccination HI titer \\<10 (negative) to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, at least a 4-fold increase in postvaccination HI titer. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), the criterion is met if the percentage of subjects achieving seroconversion/significant increase is \\>40% in the ≥18 to ≤60 years of age group or \\>30% in the ≥61 years of age group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"68","spread":null},{"groupId":"OG003","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratio of Subjects After One Vaccination of cTIV or TIV","description":"Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI Geometric Mean Titers (GMTs), three weeks after (day 22) one vaccination of cTIV or TIV. In compliance with the requirements of the EMEA recommendations (CPMP/BWP/2490/00, CPMP/BWP/214/96), this criterion is met if the GMR (day 22/day 1) in HI antibody titer is \\>2.5 in the ≥18 to ≤60 years of age group or \\>2.0 in the ≥61 years of age group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"5.74","spread":null},{"groupId":"OG003","value":"5.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.99","spread":null},{"groupId":"OG001","value":"7.08","spread":null},{"groupId":"OG002","value":"7.25","spread":null},{"groupId":"OG003","value":"8.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"9.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination","description":"The solicited local and systemic reactions were collected from day 1 up to and including day 7 after vaccination for both the vaccine groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"37","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"111","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"69","spread":null},{"groupId":"OG003","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"73","spread":null},{"groupId":"OG003","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":652},"commonTop":["Injection site pain","Injection site erythema","Headache","Fatigue","Malaise"]}}}